Improvement of atopic dermatitis with dupilumab occurs equally well across different anatomical regions: data from phase III clinical trials.

Blauvelt, A; Rosmarin, D; Bieber, T; Simpson, E L; Bagel, J; Worm, M; Deleuran, M; Katoh, N; Kawashima, M; Shumel, B; Chen, Z; Rossi, A B; Hultsch, T; Ardeleanu, M

Blauvelt, A; Rosmarin, D; Bieber, T; Simpson, E L; Bagel, J; Worm, M; Deleuran, M; Katoh, N; Kawashima, M; Shumel, B; Chen, Z; Rossi, A B; Hultsch, T; Ardeleanu, M.

Br J Dermatol ; 181(1): 196-197, 2019 07.

Article in En | MEDLINE | ID: mdl-30719707

Subject(s)

Antibodies, Monoclonal, Humanized/administration & dosage; Dermatitis, Atopic/drug therapy; Skin/drug effects; Antibodies, Monoclonal, Humanized/adverse effects; Clinical Trials, Phase III as Topic; Dermatitis, Atopic/diagnosis; Dermatitis, Atopic/immunology; Humans; Interleukin-4 Receptor alpha Subunit/antagonists & inhibitors; Interleukin-4 Receptor alpha Subunit/immunology; Severity of Illness Index; Skin/immunology; Treatment Outcome

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Skin / Dermatitis, Atopic / Antibodies, Monoclonal, Humanized Type of study: Diagnostic_studies Limits: Humans Language: En Year: 2019 Type: Article

Fulltext

XML

PubMed Links

Search on Google